Press Releases<< Back
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
"Precision medicine is no longer just a promise - it is a reality for the more than 700,000 cancer patients tested to date for whom Oncotype DX has individualized care based on the biology of their tumor," said
In addition, the American Joint Committee on Cancer (AJCC) recently incorporated the Oncotype DX test in its updated published Eighth Edition AJCC Cancer Staging Manual, identifying Oncotype DX as the only multi-gene test with Level I evidence to determine formal staging of breast cancer patients, based on prospective outcomes in more than 63,000 patients.
New data presented last week at the
Three studies involving more than 8,000 node-positive breast cancer patients showed those with a low Oncotype DX Breast Recurrence Score (RS) had excellent outcomes at five years
- An analysis of the Surveillance, Epidemiology, and End Results (SEER) registry program of the
National Cancer Institute(NCI) of 6,768 patients with lymph node-positive disease (including micrometastases) found that the five-year breast cancer-specific survival (BCSS) rate was excellent for those with a RS of less than 18, particularly among those with micrometastases and fewer positive lymph nodes. Five-year BCSS outcomes for those with a RS less than 18 ranged from 98.9 percent for those with micrometastases to 92.8 percent for those with four or more positive nodes. The RS was strongly predictive of BCSS among patients with micrometastases or one to three positive lymph nodes (both p < 0.001). These findings in node-positive disease were recently updated and published in Breast Cancer Researchand Treatment, providing further detail on the five-year outcomes results previously published in Nature Partner Journals Breast Cancer.
- A study from
Clalit Health Servicesin Israelfollowed over 700 patients for a median of 5.9 years. The results showed that patients with a RS less than 18 with micrometastases and one to three positive nodes had very good outcomes with the rates of distant recurrence of three percent at five years. The majority of these patients (93 percent) were treated with hormonal therapy alone.
- A prospective analysis of more than 770 patients from the Plan B trial conducted by the West German Study Group in Germany showed that patients with a RS of 11 or less had an excellent five-year disease free survival rate of 94 percent when treated with hormone therapy alone without chemotherapy.
Collectively, these results are consistent with two separate comprehensive reviews conducted by independent physician groups who have used the Oncotype DX Breast Recurrence Score in clinical practice when treating node-positive patients. A comprehensive summary led by
Multiple studies from
- A detailed budget impact assessment in
Germanycomparing the Breast Recurrence Score to other prognostic-only genomic tests identified the Breast Recurrence Score as the test associated with the highest reduction in chemotherapy use because it appropriately classifies more patients as low risk than other assays, resulting in net budget savings of more than EUR 4,001per patient.
- Two studies from
France, including a treatment decision analysis based on real-world clinical experience in 827 patients, demonstrated that the test significantly reduced the use of chemotherapy by 35 percent.
These results are consistent with findings from a review of eight other international studies that included more than 2,500 patients and demonstrated that Breast Recurrence Score testing led to an approximate 40 percent reduction in chemotherapy use in node-negative breast cancer.
"These new findings, based on results from thousands of patients in the
About Oncotype DX®
The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX Breast Recurrence Score, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the Breast DCIS Score™ predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. With more than 700,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeDX.com or www.MyBreastCancerTreatment.org.
About Genomic Health
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our business model; the applicability of clinical study results to actual outcomes; the impact of results from clinical studies on market adoption and utilization of Oncotype DX® tests, our ability to develop and commercialize new tests and expand into new markets domestically and internationally; unanticipated costs or delays in research and development efforts; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's quarterly report on Form 10-K for the year ended December 31, 2016. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo,
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/multiple-presentations-at-15th-st-gallen-international-breast-cancer-conference-demonstrate-significant-impact-of-oncotype-dx-breast-recurrence-score-in-reducing-burden-and-cost-of-chemotherapy-300425883.html
News Provided by Acquire Media